Pleiotropic effects of the Rho-kinase inhibitor fasudil after subarachnoid hemorrhage: A review of preclinical and clinical studies

Current Vascular Pharmacology

Volumn 12, Issue 5, 2014, Pages 758-765

  Satoh, Shin Ichi ^a   Ikegaki, Ichiro ^a   Kawasaki, Koh ^a   Asano, Toshio ^a   Shibuya, Masato ^b  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b CHUKYO HOSPITAL   (Japan)

Author keywords

Cerebral vasospasm; Fasudil; Hydroxyfasudil; Pleiotropic therapeutic effects; Rho kinase; Subarachnoid hemorrhage

Indexed keywords

ABELSON KINASE; ANGIOTENSIN II; COMPLEMENT COMPONENT C5A; ENDOTHELIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FASUDIL; HYDROXYFASUDIL; NIMODIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN F2 ALPHA; RHO KINASE; SEROTONIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; PROTEIN KINASE INHIBITOR;

ARTICLE; BLOOD VISCOSITY; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN VASOSPASM; CELL MIGRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MUSCLE CONTRACTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; VASCULAR SMOOTH MUSCLE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GENETIC PLEIOTROPY; HUMANS; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

EID: 84924153020     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140613115813     Document Type: Article

References (78)

1. Grasso G. An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage. Brain Res Rev 2004; 44(1): 49-63.
2. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for the small GTP binding protein Rho. EMBO J 1996; 15(9): 2208-16.
3. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25(9): 1767-75.
4. McGown CC, Brown NJ, Hellewell PG, et al. ROCK induced inflammation of the microcirculation during endotoxemia mediated by nitric oxide synthase. Microvasc Res 2011; 81(3): 281-8.
5. Pineda AAM, Minohara M, Kawamura N, et al. Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis. J Neurol Sci 2011; 306(1-2): 115-20.
6. Morikawa A, Sone T, Asano T. 5-isoquinolinesulfonamide derivatives. III. Synthesis and vasodilatory activity of 1-(5-isoquinolinesulfonyl)piperazine derivatives. Chem Pharm Bull 1992; 40(3): 770-3.
7. Asano T, Suzuki T, Tsuchiya M, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 1989; 98(4): 1091-100.
8. Sasaki Y, Sasaki Y. Inhibition of myosin light chain phosphorylation in cultured smooth muscle cells by HA1077, a new type of vasodilator. Biochem Biophys Res Commun 1990; 171(3): 1182-7.
9. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg 1992; 76(4): 571-7.
10. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389(6654): 990-4.
11. th Spasm Symposium. Surg Neurol Int 2011; 2: 74.
12. Sato M, Tani E, Fujikawa H, et al. Involvement of Rho-kinasemediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000; 87(3): 195-200.
13. Miyagi Y, Carpenter RC, Meguro T, et al. Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 2000; 93(3): 471-6.
14. Kawasaki K, Yano K, Sasaki K, et al. Correspondence between neurological deficit, cerebral infarct size, and Rho-kinase activity in a rat cerebral thrombosis model. J Mol Neurosci 2009; 39(1-2): 59-68.
15. Yagita Y, Kitagawa K, Sasaki T, et al. Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J Neurosci Res 2007; 85(11): 2460-9.
16. Yamashita K, Kotani Y, Nakajima Y, et al. Fasudil, a Rho kinase(ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 2007; 1154: 215-24.
17. Feske SK, Sorond FA, Henderson GV, et al. Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res 2009; 1257: 89-93.
18. Nagumo H, Sasaki Y, Ono Y, et al. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol 2000; 278(1): C57-65.
19. Yano K, Kawasaki K, Hattori T, et al. Demonstration of elevation and localization of Rho-kinase activity in the brain of a rat model of cerebral infarction. Eur J Pharmacol 2008; 594(1-3): 77-83.
20. Satoh S, Takayasu M, Kawasaki K, et al. Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. J Pharmacol Sci 2012; 118(1): 92-8.
21. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351(1): 95-105.
22. Sugimoto M, Nakayama M, Goto TM, et al. Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells. Biochem Biophys Res Commun 2007; 361: 462-7.
23. Satoh S, Toshima Y, Hitomi A, et al. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res 2008; 1193: 102-8.
24. Takemoto M, Sun J, Hiroki J, et al. Rho-kinase mediates hypoxiainduced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106(1): 57-62.
25. Suzuki Y, Shibuya M, Satoh S, et al. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: Sub-analysis of the post-marketing surveillance study. Neurol Med Chir 2008; 48(6): 241-8.
26. Hanada Y, Kudo H, Kohmura E. Chronologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 2005; 14(2): 47-9.
27. Asano T, Ikegaki I, Satoh S, et al. Endothelin: a potential modulator of cerebral vasospasm. Eur J Pharmacol 1990; 190(3): 365-72.
28. Takayasu M, Dacey RG Jr. Effects of HA1077, a novel calciumantagonistic spasmolytic agent on intracerebral arterioles of rats. Acta Neurochir 1990; 103(1-2): 67-70.
29. Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxyl fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci 2001; 69(12): 1441-53.
30. Watanabe Y, Faraci FM, Heistad DD. Activation of Rho-associated kinase during augmented contraction of the basilar artery to serotonin after subarachnoid hemorrhage. Am J Physiol 2005; 288(6): H2653-8.
31. Nakamura K, Nishimura J, Hirano K, et al. Hydroxyfasudil, an active metabolite of fasudil hydrochloride, relaxes the rabbit basilar artery by disinhibition of myosin light chain phosphatase. J Cereb Blood Flow Metab 2001; 21(7): 876-85.
32. Asano T, Ikegaki I, Satoh S, et al. A protein kinase inhibitor, fasudil(AT-877): A novel approach to signal transduction therapy. Cardiovasc Drug Rev 1998; 16(1): 76-87.
33. Zoerle T, Ilodigwe DC, Wan H, et al. Pharmacologic reduction of angiographic vasospasm in experimental subarachnoid hemorrhage: systematic review and meta-analysis. J Cereb Blood Flow Metab 2012; 32(9): 1645-58.
34. Takayasu M, Suzuki Y, Shibuya M, et al. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J Neurosurg 1986; 65(1): 80-5.
35. Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987; 241(3): 1033-40.
36. 2+ antagonist and vasodilator, on chronic cerebral vasospasm. Eur J Pharmacol 1992; 220(2-3): 243-8.
37. Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12(3): 329-41.
38. van Hinsbergh VW, van Nieuw Amerongen GP. Intracellular signaling involved in modulating human endothelial barrier function. J Anat 2002; 200(6): 549-60.
39. Suzuki Y, Satoh S, Kimura M, et al. Effects of vasopressin and oxytocin on canine cerebral circulation in vivo. J Neurosurg 1992; 77(3): 424-31.
40. Chrissobolis S, Miller AA, Drummond GR, et al. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front Biosci 2011; 16: 1733-45.
41. Ayer RE, Zhang JH. Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm. Acta Neurochir 2008; 104: 33-41.
42. Shin HK, Salomone S, Potts EM, et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 2007; 27(5): 998-1009.
43. Rikitake Y, Kim H-H, Huang Z, et al. Inhibition of Rho kinase(ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36(10): 2251-7.
44. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ Res 2003; 93(8): 767-75.
45. Thomas WS, Mori E, Copeland BR, et al. Tissue factor contributes to microvascular defects after focal cerebral ischemia. Stroke 1993; 24(6): 847-54.
46. Kappelmayer J, Berecki M, Misz M, et al. Monocytes express tissue factor in young patients with cerebral ischemia. Cerebrovasc Dis 1998; 8(4): 235-9.
47. Mechtcheriakova D, Schabbauer G, Lucerna M, et al. Specificity, diversity, and convergence in VEGF and TNF-dddsignaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15(1): 230-42.
48. Satoh S, Hitomi A, Ikegaki I, et al. Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull 2010; 81(1): 191-5.
49. Ishibashi T, Sakamoto T, Ohkawara H, et al. Integral role of RhoA activation in monocyte adhesion-Triggered tissue factor expression in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23(4): 681-7.
50. Breslin JW, Yuan SY. Involvement of RhoA and Rho kinase in neutrophil-stimulated endothelial hyperpermeability. Am J Physiol 2004; 286(3): H1057-62.
51. Satoh S, Ikegaki I, Suzuki Y, et al. Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br J Pharmacol 1996; 118(7): 1592-96.
52. Satoh S, Yamamoto Y, Toshima Y, et al. Fasudil, a protein kinase inhibitor, prevents the development of endothelial injury and neutrophil infiltration in a two-haemorrhage canine model. J Clin Neurosci 1999; 6(5): 394-9.
53. Suzuki Y, Yamamoto M, Wada H, et al. Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. Blood 1999; 93(10): 3408-17.
54. Paul BZS, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and-independent signaling pathways. J Biol Chem 1999; 274(40): 28293-300.
55. Toshima Y, Satoh S, Ikegaki I, et al. Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm. Life Sci 1997; 61(14): 1371-7.
56. Grubb RL Jr, Raichle ME, Eichling JO, et al. Effects of subarachnoid hemorrhage on cerebral blood volume, blood flow, and oxygen utilization in humans. J Neurosurg 1977; 46(4): 446-53.
57. Satoh S, Suzuki Y, Ikegaki I, et al. The effects of HA1077 on the cerebral circulation after subarachnoid haemorrhage in dogs. Acta Neurochir 1991; 110(3-4): 185-8.
58. Shibuya M, Ikeda A, Ohsuka K et al. Fasudil(a rho-kinase inhibitor) may specifically increase rCBF in spastic area. Acta Neurochir 2008; 104: 275-8.
59. Iwabuchi S, Yokouchi T, Hayashi M, et al. Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage-Analysis of time-density curve with digital subtraction angiography-. Neurol Med Chir 2006; 46(11): 535-40.
60. Hitomi A, Satoh S, Ikegaki I, et al. Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci 2000; 67(16): 1929-39.
61. Osuka K, Suzuki Y, Tanazawa T, et al. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir 1998; 140(9): 943-51.
62. Sarrafzadeh A, Schlenk F, Gericke C, et al. Relevance of cerebral interleukin-6 after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2010; 13(3): 339-46.
63. Nakura T, Osuka K, Inukai T, et al. Soluble gp130 regulates interleukin-6 in cerebrospinal fluid after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2011; 82(9): 952-4.
64. Takizawa T, Tada T, Kitazawa K, et al. Inflammatory cytokine cascade released by leukocytes in cerebrospinal fluid after subarachnoid hemorrhage. Neurol Res 2001; 23(7): 724-30.
65. 222, in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage participates in the pathogenesis of delayed cerebral vasospasm. Neurosci Lett 2005; 373(3): 222-5.
66. Nakahara T, Tsuruta R, Kaneko T, et al. High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage. Neurocrit Care 2009; 11(3): 362-8.
67. Provencio JJ, Fu X, Siu A, et al. CSF neutrophils are implicated in the development of vasospasm in subarachnoid hemorrhage. Neurocrit Care 2010; 12(2): 244-51.
68. Satoh S, Kobayashi T, Hitomi A, et al. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 1999; 80(1): 41-8.
69. Satoh S, Yamaguchi T, Hitomi A, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 2002; 455(2-3): 169-74.
70. Arai M, Sasaki Y, Nozawa R. Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem Pharmacol 1993; 46(8): 1487-90.
71. Zhao J, Zhou D, Guo J, et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: Final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir 2011; 51(10): 679-83.
72. Suzuki Y, Shibuya M, Satoh S, et al. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007; 68(2): 126-32.
73. Nakashima S, Tabuchi K, Shimokawa S, et al. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir 1998; 38(12): 805-11.
74. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105(13): 1545-7.
75. Inokuchi K, Ito A, Fukumoto Y, et al. Usefulness of fasudil, a Rhokinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol 2004; 44(3): 275-7.
76. Watanabe G, Yamaguchi S, Takagi T, et al. Potent vasodilatory effect of fasudil on radial artery graft in coronary artery bypass operations. Ann Thorac Surg 2014; 97(3): 845-50.
77. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91(3): 391-2.
78. Fukumoto Y, Yamada N, Matsubara H, et al. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension. Circ J 2013; 77(10): 2619-25.